AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
AEGON ASSET MANAGEMENT UK Plc Decreases Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)
AEGON ASSET MANAGEMENT UK Plc reduced its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT – Get Rating) by 6.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 438,371 shares of the biotechnology company's stock after selling 32,440 shares during the quarter. AEGON ASSET MANAGEMENT UK Plc owned 0.61% of Veracyte worth $8,719,000 at the end of the most recent quarter.
據Veracyte,Inc.在提交給美國證券交易委員會的最新信息中稱,Aegon資產管理英國公司在第二季度減持了6.9%的Veracyte,Inc.股票。該公司在本季度出售了32,440股後,持有438,371股這家生物技術公司的股票。截至最近一個季度末,Aegon資產管理公司UK Plc擁有Veracyte 0.61%的股份,價值8,719,000美元。
Several other institutional investors also recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of Veracyte during the first quarter worth $33,000. Quantbot Technologies LP acquired a new stake in Veracyte in the first quarter valued at $73,000. Lazard Asset Management LLC raised its holdings in Veracyte by 46.3% in the first quarter. Lazard Asset Management LLC now owns 3,410 shares of the biotechnology company's stock valued at $94,000 after acquiring an additional 1,079 shares in the last quarter. Prospera Financial Services Inc acquired a new stake in Veracyte in the first quarter valued at $127,000. Finally, Vienna Asset Management LLC acquired a new stake in Veracyte in the fourth quarter valued at $147,000.
其他幾家機構投資者最近也買賣了該公司的股票。Point72 Hong Kong Ltd在第一季度收購了價值33,000美元的Veracyte股票的新頭寸。Quantbot Technologies LP在第一季度收購了Veracyte的新股份,價值7.3萬美元。Lazard Asset Management LLC在第一季度將其在Veracyte的持股增加了46.3%。Lazard Asset Management LLC現在擁有3410股這家生物技術公司的股票,價值94,000美元,上個季度又購買了1,079股。普羅斯佩拉金融服務公司在第一季度收購了Veracyte的新股份,價值12.7萬美元。最後,維也納資產管理有限責任公司在第四季度收購了Veracyte的新股份,價值14.7萬美元。
Veracyte Stock Performance
Veracyte股票表現
Shares of Veracyte stock traded down $0.33 during trading on Monday, hitting $18.14. 23,586 shares of the stock were exchanged, compared to its average volume of 938,363. The stock's fifty day moving average is $23.36 and its 200 day moving average is $22.39. The stock has a market cap of $1.30 billion, a PE ratio of -26.82 and a beta of 1.17. Veracyte, Inc. has a 12 month low of $14.85 and a 12 month high of $54.13.
在週一的交易中,Veracyte的股價下跌了0.33美元,跌至18.14美元。該股成交量為23,586股,而平均成交量為938,363股。該股的50日移動均線切入位為23.36美元,200日移動均線切入位為22.39美元。該股市值為13億美元,市盈率為-26.82,貝塔係數為1.17。Veracyte,Inc.的12個月低點為14.85美元,12個月高位為54.13美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
VCYT has been the topic of a number of research reports. Raymond James increased their target price on shares of Veracyte from $30.00 to $31.00 and gave the stock an "outperform" rating in a report on Thursday, August 4th. Needham & Company LLC increased their target price on shares of Veracyte from $26.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, August 3rd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.
VCYT已經成為許多研究報告的主題。雷蒙德·詹姆斯在8月4日週四的一份報告中將Veracyte的股票目標價從30.00美元上調至31.00美元,並給予該股“跑贏大盤”的評級。Needham&Company LLC在8月3日(星期三)的一份報告中將Veracyte的股票目標價從26.00美元上調至31.00美元,並給予該股“買入”評級。一名分析師對該股的評級為賣出,六名分析師對該股的評級為買入。根據MarketBeat的數據,該股目前的共識評級為“適度買入”,共識目標價為42.50美元。
Veracyte Profile
Veracyte配置文件
(Get Rating)
(獲取評級)
Veracyte, Inc operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis.
Veracyte,Inc.是一家全球性的診斷公司。該公司提供Afirma基因組測序分類器和Xpression Atlas,用於確定結果不確定的患者是否為良性疾病,以避免不必要的手術;解密前列腺癌活檢和根治性前列腺癌切除術;Prosigna乳腺癌檢測用於乳腺癌診斷;Percepta基因組測序分類器和Percepta鼻拭子測試用於肺癌診斷;Envisia基因組分類器用於診斷間質性肺部疾病,包括特發性肺纖維化;免疫結腸癌檢測用於結腸癌診斷。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Veracyte (VCYT)
- Still Lovin' It: Investors Keep Visiting McDonald's
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger's is Your One-Stop Consumer Staples Stock
- 免費獲取StockNews.com關於Veracyte的研究報告(VCyT)
- 仍然愛着它:投資者繼續光顧麥當勞
- 聯邦快遞剛剛提供了一個買入機會嗎?
- 自動區重新進入拉力賽模式,新高在望
- Upwork股價跌入便宜貨領域
- 克羅格百貨是你的一站式消費者史泰博股票
Want to see what other hedge funds are holding VCYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veracyte, Inc. (NASDAQ:VCYT – Get Rating).
想看看還有哪些對衝基金持有VCYT嗎?訪問HoldingsChannel.com獲取Veracyte,Inc.(納斯達克代碼:VCyt-Get Rating)的最新13F備案文件和內幕交易信息。
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
接受Veracyte Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Veracyte和相關公司的最新新聞和分析師評級的每日簡要摘要。